Molecular structure of Budesonide, CAS Number: 51333-22-3
Budesonide (CAS 51333-22-3)
See product citations (3)
Alternate Names:
16,17-Butylidenebis(oxy)-11,21-dihydroxypregna-1,4-diene-3,20-dione
Application:
Budesonide is a synthetic anti-inflammatory glucocorticoid
CAS Number:
51333-22-3
Purity:
>98%
Molecular Weight:
430.50
Molecular Formula:
C25H34O6
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Budesonide is a synthetic anti-inflammatory glucocorticoid that displays chemopreventive activity. Budesonide prevents formation of lung adenomas and adenocarcinomas in mice following inhalation or oral administration. Reverses DNA hypomethylation and modulates expression of cancer-related genes.
Budesonide (CAS 51333-22-3) References
- Inhaled budesonide/formoterol combination. | McGavin, JK., et al. 2001. Drugs. 61: 71-8; discussion 79-80. PMID: 11217872
- Budesonide/formoterol: a review of its use in asthma. | Goldsmith, DR. and Keating, GM. 2004. Drugs. 64: 1597-618. PMID: 15233594
- Pharmacokinetics of budesonide (Entocort EC) capsules for Crohn's disease. | Edsbäcker, S. and Andersson, T. 2004. Clin Pharmacokinet. 43: 803-21. PMID: 15355126
- Modulation by budesonide of DNA methylation and mRNA expression in mouse lung tumors. | Pereira, MA., et al. 2007. Int J Cancer. 120: 1150-3. PMID: 17163412
- Budesonide Multi-matrix for the Treatment of Patients with Ulcerative Colitis. | Lichtenstein, GR. 2016. Dig Dis Sci. 61: 358-70. PMID: 26541989
- Budesonide for the treatment of ulcerative colitis. | Abdalla, MI. and Herfarth, H. 2016. Expert Opin Pharmacother. 17: 1549-59. PMID: 27157244
- Oral budesonide in gastrointestinal and liver disease: A practical guide for the clinician. | Miehlke, S., et al. 2018. J Gastroenterol Hepatol.. PMID: 29603368
- Reviewing the therapeutic role of budesonide in Crohn's disease. | López-Sanromán, A., et al. 2018. Gastroenterol Hepatol. 41: 458-471. PMID: 30007787
- Budesonide versus systemic corticosteroids in IgA Nephropathy: A retrospective, propensity-matched comparison. | Ismail, G., et al. 2020. Medicine (Baltimore). 99: e21000. PMID: 32590815
- Budesonide in the first line treatment of patients with autoimmune hepatitis. | Olivas, I., et al. 2022. Gastroenterol Hepatol. 45: 561-570. PMID: 34923033
- A meta-analysis on randomized controlled trials of treating eosinophilic esophagitis with budesonide. | Liu, X., et al. 2022. Ann Med. 54: 2078-2088. PMID: 35862288
- Budesonide. A review of its pharmacological properties and therapeutic efficacy in inflammatory bowel disease. | Spencer, CM. and McTavish, D. 1995. Drugs. 50: 854-72. PMID: 8586030
- Chemoprevention of pulmonary carcinogenesis by aerosolized budesonide in female A/J mice. | Wattenberg, LW., et al. 1997. Cancer Res. 57: 5489-92. PMID: 9407956
Inhibitor of:
β-defensin 125, β-defensin 47, β-defensin 5, CD163L1, EG626305, IL-12A p35, IL-13, Il-28a, IL-5, Mucin 2L, Olfr371, Olfr633, Olfr665, RSHL3, Tenascin-X, and UGRP1.Activator of:
CLCA1_Clac1, Ear5, galectin-9, GMEB-1, Macrophagee Marker, MHC class II DQ, Mucin 22, Olfr702, and SP-B.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Budesonide, 50 mg | sc-202980 | 50 mg | $77.00 | |||
Budesonide, 100 mg | sc-202980A | 100 mg | $88.00 | |||
Budesonide, 200 mg | sc-202980B | 200 mg | $151.00 | |||
Budesonide, 500 mg | sc-202980C | 500 mg | $343.00 |